Antidepressants in children and adolescents with major depressive disorder and the influence of placebo response: A meta-analysis

There are few available antidepressants for pediatric Major Depressive Disorder (MDD). The objective of this systematic review and meta-analysis was to review industry-funded studies of antidepressants in children and adolescents with MDD, and to better understand the contribution of study design an...

Full description

Saved in:
Bibliographic Details
Published in:Journal of affective disorders 2022-05, Vol.305, p.55-64
Main Authors: Feeney, Anna, Hock, Rebecca S., Fava, Maurizio, Hernández Ortiz, Jesús M., Iovieno, Nadia, Papakostas, George I.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Antidepressant
Antidepressive Agents - therapeutic use
Child
Clinical trials
Depressive Disorder, Major - drug therapy
Double-Blind Method
Humans
Major depressive disorder
Pediatric depression
Placebo
Placebo Effect
Randomized Controlled Trials as Topic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are few available antidepressants for pediatric Major Depressive Disorder (MDD). The objective of this systematic review and meta-analysis was to review industry-funded studies of antidepressants in children and adolescents with MDD, and to better understand the contribution of study design and placebo response to the findings of these studies. Randomized, double-blind, placebo-controlled clinical trials that compared antidepressant with placebo for the acute treatment of MDD in children and/or adolescents were selected. Estimates of the standardized mean difference (SMD) in change in Children's Depression Rating Scale-Revised scores were pooled, after examining for heterogeneity. A random-effects meta-analysis was completed. Thirty-four antidepressant-placebo comparisons, involving 6161 subjects, were included. The SMD among all studies was 0.12 (CI 0.08, 0.17; p 
ISSN:0165-0327
1573-2517
DOI:10.1016/j.jad.2022.02.074